Home > Education : Histology and Molecular Markers in NSCLC
Performance Improvement: Histology and Molecular Markers in Non-small Cell Lung Cancer
Practicing oncologists involved in the treatment of non-small cell lung cancer (NSCLC) are invited to participate in a Performance Improvement (PI) CME activity unlike any other.
Positively impact the outcomes of patients you treat every day and affect the treatment of patients nationwide!
Beginning with a self-assessment questionnaire and a brief chart data abstraction, participants will have the opportunity to review current practice patterns. They will create an "Action Plan," to help schedule and track their participation. Upon completion of an "Action Plan," participants will then have an opportunity to reassess their practices through additional self-assessment and chart data abstraction activities.
The project is slated to begin in March 2012.
Objectives:
- To develop a case-based clinical vignette tool to determine the current practice patterns of oncologists and assess perceptions, attitudes, and barriers that providers face in managing their patients with NSCLC.
- To provide continuing medical education activities that provide a pathway to practice improvement in the treatment of patients with NSCLC.
- To develop educational materials to help patients with NSCLC choose a treatment plan, make the most of clinical visits, and understand treatment-related side effects, nutrition management of side effects, the importance of adherence to treatment, and how to maintain a healthy lifestyle.
CME activities will help physicians interpret pathology reports, apply pathology data in treatment selection, interpret data for treatment response, and understand the overall impact on patient quality of life.
This PI CME initiative will provide up to 20 AMA PRA Category 1 Credits™ based on the number of sections participating centers complete.
Background and Rationale:
Community oncologists who treat patients with lung cancer need access to new information, tools, and insights, which they can integrate into their practice to improve patient outcomes. ACCC's educational initiative offers community physicians the opportunity to improve their professional practice in the care of patients with lung cancer.
Advances in understanding the pathogenesis of NSCLC have led to the development of molecularly targeted agents, including those targeting vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), epidermal growth factor (EGF), and insulin-like growth factor (IGF-I) signaling. Today, tumor histology and molecular characteristics are critical clinical selection criteria for individualizing treatment.
Anecdotally, we know that community oncologists often order pathology tests, but many fail to routinely utilize the molecular and histologic pathology data to guide diagnosis, treatment selection, and predict response to therapy. The rapid evolution of the treatment paradigm for NSCLC has generated knowledge and practice gaps that this educational initiative seeks to bridge.
ACCC's MyNetwork
Facebook
LinkedIn
Twitter
ACCC Vision Channel